about
Enteral nutrition formulations for acute pancreatitisPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CPeginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CPegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis CDiagnosis of Irritable Bowel Syndrome: Role of Potential BiomarkersCrohn's disease in womenMinimally invasive treatment of pancreatic pseudocystsTransient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Cognitive behavioral approach to understanding irritable bowel syndrome.Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.Direct-acting antivirals for chronic hepatitis C.Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done?Sudden death after endoscopic retrograde cholangiopancreatography (ERCP)--case report and literature review.FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.Early nasojejunal tube feeding versus nil-by-mouth in acute pancreatitis: A randomized clinical trial.Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity.Attentional biases in irritable bowel syndrome patients.Erratum to: Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.Erythrocyte sedimentation rate - possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients.Differences in the health-related quality of life, affective status, and personality between irritable bowel syndrome and inflammatory bowel disease patients.Direct-acting antivirals for chronic hepatitis CReply:Reply:Pegylated interferon alpha 2a for chronic hepatitis CWho is wrong? Responses to Kwo et alSolitary pulmonary hematoma--unusual complication of thrombolytic treatmentIs there any connection between severity of acute pancreatitis and electrocardiographic changes?Video capsule retention--endoscopic or surgical problem?Mycophenolate mofetil induced severe, life threatening lower gastrointestinal bleeding - case reportResponse to Munteanu et alERCP induced and non-ERCP-induced acute pancreatitis: Two distinct clinical entities?
P50
Q24187179-705F8A29-91ED-4810-A1D3-1BB3FBC052E9Q24200189-CC1519A1-436B-4306-BBA2-416DFDE7C9A4Q24200197-1E78EA66-09C8-428C-916D-BD996E134F6CQ24240315-6D2C8668-5055-44CC-BAE4-EB5A14DB7196Q26823844-2C8D4711-58DF-4F4F-8676-BEB4C7D2468BQ26851451-65D0C095-0A8A-4F89-8D24-8531FC15C93AQ26864723-6CB27252-458E-493D-84A3-2A8C5D10A994Q28079445-8D01C2D5-2137-4082-9746-BDD5981BA551Q30436514-4591A0E8-91E5-4E1B-ADCA-235C56406758Q33464907-31230AE2-5E7F-4869-8D45-2513211BBBEEQ34100819-5C6D56DE-A537-4CA7-9CF0-0113EFCFAD15Q34557595-DAED667F-EBEB-4F4F-B386-2CC1C03B24FCQ35012013-DFD4BB02-C128-4C99-9FA1-F52633842229Q36152551-AAE13277-E627-4E56-9FF3-4351A1F9E409Q38188809-D72CAB2E-3F28-415B-8F38-53BFF2109060Q40702044-DBDC6177-CC7E-418E-BD86-D0FB77F01EF0Q48024579-4B30CDA7-253D-4DD9-A969-1CB6534E7990Q48081659-6561D051-4EF2-42A0-996A-EAC1267DED1CQ48244269-D1DF225B-8F10-41E6-9992-F2FB5D0A7ABDQ48249001-1632C9ED-E777-44AF-AC31-923F75D11D45Q48453933-AD487456-A457-4D8D-B0F4-54DDADE01D5CQ49068641-1BCDF5C4-58C6-44CA-9C5A-5CA3B65F70C3Q57389418-A411CEB1-347D-4158-A10A-168FD48A11CEQ57389535-295A2FEA-4606-4206-81E3-C5EF548DDBF1Q57389569-71A061CB-64F2-49D6-81CF-D668CFADCFC3Q57389603-A2817696-6716-4628-99CD-8AF8554630B0Q58040808-606575AD-02B7-4542-9FED-4CDC9D5CCFE3Q64046559-FC460BBC-2333-4611-B65C-772C07251C11Q79852775-40D4D7EC-8CB9-4BBC-89CA-F44FF83B7567Q84867995-241937F2-A74E-4B94-962E-344D01AE3DE1Q86017480-35171382-24CE-4AEC-838D-352EC06A3DEAQ87499893-0754F08E-EBF8-479D-9CF5-BD5FCCCB9F58Q88012485-2F60CE1F-CF1C-4190-962C-58CE50E1170B
P50
description
researcher ORCID ID = 0000-0002-4758-1717
@en
wetenschapper
@nl
name
Goran Hauser
@ast
Goran Hauser
@en
Goran Hauser
@es
Goran Hauser
@nl
type
label
Goran Hauser
@ast
Goran Hauser
@en
Goran Hauser
@es
Goran Hauser
@nl
prefLabel
Goran Hauser
@ast
Goran Hauser
@en
Goran Hauser
@es
Goran Hauser
@nl
P106
P214
153146094146200330372
P31
P496
0000-0002-4758-1717
P7859
viaf-153146094146200330372